Caspofungin prolongs survival of transiently neutropenic rats with advanced-stage invasive pulmonary aspergillosis

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 4, 2008, Pages 1345-1350

  Van De Sande, Wendy W J ^a   Van Vianen, Wim ^a   Ten Kate, Marian T ^a   Vissers, Jolanda ^a   Laurijsens, John ^a   Tavakol, Mehri ^a   Rijnders, Bart J A ^a   Mathot, Ron A A ^a   Bakker Woudenberg, Irma A J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CASPOFUNGIN; CREATININE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; INOCULATION; LUNG ASPERGILLOSIS; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; RAT; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; DISEASE MODELS, ANIMAL; ECHINOCANDINS; HUMANS; LUNG; LUNG DISEASES, FUNGAL; NEUTROPENIA; RATS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 42049107509     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00536-07     Document Type: Article

References (19)

1. Abruzzo, G. K., C. J. Gill, A. M. Flattery, L. Kong, C. Leighton, J. G. Smith, V. B. Pikounis, K. Bartizal, and H. Rosen. 2000. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob. Agents Chemother. 44:2310-2318.
2. Becker, M. J., S. de Marie, M. H. Fens, H. A. Verbrugh, and I. A. Bakker-Woudenberg. 2003. Effect of amphotericin B treatment on kinetics of cytokines and parameters of fungal load in neutropenic rats with invasive pulmonary aspergillosis. J. Antimicrob. Chemother. 52:428-434.
3. Becker, M. J., S. de Marie, D. Willemse, H. A. Verbrugh, and I. A. Bakker-Woudenberg. 2000. Quantitative galactomannan detection is superior to PCR in diagnosing and monitoring invasive pulmonary aspergillosis in an experimental rat model. J. Clin. Microbiol. 38:1434-1438.
4. Betts, R., A. Glasmacher, J. Maertens, G. Maschmeyer, J. A. Vazquez, H. Teppler, A. Taylor, R. Lupinacci, C. Sable, and N. Kartsonis. 2006. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer 106:466-473.
5. Bowman, J. C., G. K. Abruzzo, J. W. Anderson, A. M. Flattery, C. J. Gill, V. B. Pikounis, D. M. Schmatz, P. A. Liberator, and C. M. Douglas. 2001. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob. Agents Chemother. 45:3474-3481.
6. Clemons, K. V., R. A. Sobel, and D. A. Stevens. 2000. Toxicity of LY303366, an echinocandin antifungal, in mice pretreated with glucocorticoids. Antimicrob. Agents Chemother. 44:378-381.
7. Clemons, K. V., and D. A. Stevens. 2006. Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis. Med. Mycol. 44:69-73.
8. Council of the European Commission. 1986. Guidelines on the protection of experimental animals. European Commission, Brussels, Belgium.
9. Fontaine, T., C. Simenel, G. Duhreucq, O. Adam, M. Delepierre, J. Lemoine, C. E. Vorgias, M. Diaquin, and J. P. Latge. 2000. Molecular organization of the alkali-insoluble fraction of Aspergillus fumigatus cell wall. J. Biol. Chem. 275:27594-27607.
10. Groll, A. H., D. Mickiene, R. Petraitiene, V. Petraitis, C. A. Lyman, J. S. Bacher, S. C. Piscitelli, and T. J. Walsh. 2001. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob. Agents Chemother. 45:2845-2855.
11. Maertens, J., I. Raad, G. Petrikkos, M. Boogaerts, D. Selleslag, F. B. Petersen, C. A. Sable, N. A. Kartsonis, A. Ngai, A. Taylor, T. F. Patterson, D. W. Denning, and T. J. Walsh. 2004. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. 39:1563-1571.
12. Maschmeyer, G., and A. Glasmacher. 2005. Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin. Mycoses 48:227-234.
13. Morrison, V. A. 2006. Echinocandin antifungals: review and update. Expert. Rev. Anti-Infect. Ther. 4:325-342.
14. Petraitiene, R., V. Petraitis, A. H. Groll, T. Sein, R. L. Schaufele, A. Francesconi, J. Bacher, N. A. Avila, and T. J. Walsh. 2002. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob. Agents Chemother. 46:12-23.
15. Petraitis, V., R. Petraitiene, A. H. Groll, A. Bell, D. P. Callender, T. Sein, R. L. Schaufele, C. L. McMillian, J. Bacher, and T. J. Walsh. 1998. Anti-fungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. 42:2898-2905.
16. Stone, J. A., S. D. Holland, P. J. Wickersham, A. Sterrett, M. Schwartz, C. Bonfiglio, M. Hesney, G. A. Winchell, P. J. Deutsch, H. Greenberg, T. L. Hunt, and S. A. Waldman. 2002. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob. Agents Chemother. 46:739-745.
17. van Doornum, G. J., J. Guldemeester, A. D. Osterhaus, and H. G. Niesters. 2003. Diagnosing herpesvirus infections by real-time amplification and rapid culture. J. Clin. Microbiol. 41:576-580.
18. van Vianen, W., S. de Marie, M. T. ten Kate, R. A. Mathot, and I. A. Bakker-Woudenberg. 2006. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis. J. Antimicrob. Chemother. 57:732-740.
19. Walsh, T. J., H. Teppler, G. R. Donowitz, J. A. Maertens, L. R. Baden, A. Dmoszynska, O. A. Cornely, M. R. Bourque, R. J. Lupinacci, C. A. Sable, and B. E. dePauw. 2004. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 351:1391-1402.